Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (6673)	5/19/1999 1:45:00 PM
From: Vector1	Respond to of 9719

I believe that the success of Rituxan will help Bexxar by creating acceptance in the market for MAB treatment. While first to market is important in the end the better molecule wins. Some recent examples are Avonex which hit the MS market almost a year after Betaseron and Viracept in which AGPH had to go up against marketing giants like MRK.The following are a couple of excerps from Peter Ginsbergs report after the recent ASCO conference. ------------------------------------------------- The successes of Rituxan in the treatment of non-Hodgkin's lymphoma (NHL) and Herceptin in the treatment of breast cancer have brought added exposure to the development of antibody treatments against a range of cancers. Here at the ASCO conference in Atlanta, it appears that these successes have led to expanded interest in the use of Coulter's Bexxar, which was the subject of a successful pivotal trial fully detailed last December. We also believe that interest has expanded as Bexxar trials are being readied in a number of new settings such as in combination with standard chemotherapies or in new disease settings such as chronic lymphocytic leukemia. ---------- However, one of Bexxar's clinical investigators revealed that Coulter's study of patients receiving Bexxar as first-line therapy continues to proceed exceedingly well. This study is quite important, as it could be helpful in persuading clinicians to prescribe Bexxar in earlier-stage lymphoma patients once the data are published. Last spring at ASCO, a 71% complete response rate and a 100% overall response rate were reported in an interim look at data on 24 patients followed for six months in this first-line therapy study. V1

To: scaram(o)uche who wrote (6673)	5/19/1999 10:39:00 PM
From: Bob L	Read Replies (1) \| Respond to of 9719

Nothing new on CHOP plus rituxan, but there is an ASCO abstract on Fludarabine and rituxan. I posted the link over in the IDPH thread. I've heard that rituxan is being tried with other chemos, but unfortunately can't say which.